GlobeNewswire: SANOFI Contains the last 10 of 10 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T05:00:42ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2015/06/09/743369/10137954/en/FDA-Advisory-Committee-Recommends-Approval-of-Sanofi-and-Regeneron-s-Praluent-r-alirocumab-Injection-for-Patients-with-Hypercholesterolemia.html?f=22&fvtc=4&fvtv=20697FDA Advisory Committee Recommends Approval of Sanofi and Regeneron's Praluent(r) (alirocumab) Injection for Patients with Hypercholesterolemia2015-06-09T22:47:56Z<![CDATA[PARIS and TARRYTOWN, N.Y., June 9, 2015 (GLOBE NEWSWIRE) -- ]]>https://www.globenewswire.com/news-release/2015/03/19/716579/10125543/en/Sanofi-Announces-Top-Line-Results-for-Cardiovascular-Outcomes-Study-of-Lyxumia-r-lixisenatide.html?f=22&fvtc=4&fvtv=20697Sanofi Announces Top-Line Results for Cardiovascular Outcomes Study of Lyxumia(r) (lixisenatide)2015-03-19T06:11:04Z<![CDATA[Results support resubmission of U.S. New Drug Application in Q3 2015 PARIS, March 19, 2015 (GLOBE NEWSWIRE) -- ]]>https://www.globenewswire.com/news-release/2015/03/15/715243/10124816/en/Sanofi-Regeneron-18-Month-Results-of-ODYSSEY-LONG-TERM-Trial-with-Praluent-TM-alirocumab-Published-in-The-New-England-Journal-of-Medicine.html?f=22&fvtc=4&fvtv=20697Sanofi, Regeneron: 18-Month Results of ODYSSEY LONG TERM Trial with Praluent(TM) (alirocumab) Published in The New England Journal of Medicine2015-03-15T15:14:58Z<![CDATA[Sanofi and Regeneron Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent (TM) (alirocumab) Published in The New England Journal of Medicine]]>https://www.globenewswire.com/news-release/2014/08/11/657435/10094006/en/Sanofi-and-MannKind-Announce-Global-Licensing-Agreement-for-Afrezza-R-insulin-human-Rapid-Acting-Inhaled-Insulin.html?f=22&fvtc=4&fvtv=20697Sanofi and MannKind Announce Global Licensing Agreement for Afrezza(R) (insulin human) Rapid-Acting Inhaled Insulin2014-08-11T05:12:46Z<![CDATA[PARIS and VALENCIA, Calif., Aug. 11, 2014 (GLOBE NEWSWIRE) -- ]]>https://www.globenewswire.com/news-release/2014/07/10/650047/10088982/en/First-Ever-Dengue-Vaccine-Candidate-To-Show-Efficacy-Against-Dengue-Fever-and-Dengue-Haemorrhagic-Fever-in-Asia.html?f=22&fvtc=4&fvtv=20697First Ever Dengue Vaccine Candidate To Show Efficacy Against Dengue Fever and Dengue Haemorrhagic Fever in Asia2014-07-10T23:07:32Z<![CDATA[- 88.5% reduction of Dengue Haemorrhagic Fever shown in detailed analyses of world's first phase III efficacy study published in The Lancet -]]>https://www.globenewswire.com/news-release/2014/07/09/649763/10088795/en/Sanofi-and-Regeneron-Announce-Positive-Results-from-Phase-2b-Study-of-Dupilumab-in-Patients-with-Moderate-to-Severe-Atopic-Dermatitis.html?f=22&fvtc=4&fvtv=20697Sanofi and Regeneron Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis2014-07-09T21:09:44Z<![CDATA[Results from Earlier Clinical Trials Published Today in the New England Journal of Medicine PARIS and TARRYTOWN, N.Y., July 9, 2014 (GLOBE NEWSWIRE) -- Sanofi (EURONEXT : SAN and NYSE : SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema. All doses of dupilumab met the primary endpoint of a greater improvement in Eczema Area and Severity Index (EASI) scores from baseline compared to placebo. In addition, the companies also announced that four earlier clinical studies of dupilumab in moderate-to-severe atopic dermatitis were published today in the New England Journal of Medicine (NEJM). Dupilumab is an investigational monoclonal antibody that blocks signaling of IL-4 and IL-13, two cytokines that play a key role in the pathogenesis of moderate-to-severe atopic dermatitis.]]>https://www.globenewswire.com/news-release/2014/06/14/644127/10085774/en/Sanofi-Reports-Positive-Phase-3-Results-for-Toujeo-R.html?f=22&fvtc=4&fvtv=20697Sanofi Reports Positive Phase 3 Results for Toujeo(R)2014-06-14T17:09:13Z<![CDATA[Sanofi Reports Positive Phase 3 Results for Toujeo®
(insulin glargine [rDNA origin] injection, 300 U/mL)]]>https://www.globenewswire.com/news-release/2014/05/28/639728/10083425/en/Sanofi-and-Lilly-announce-licensing-agreement-for-Cialis-R-tadalafil-OTC.html?f=22&fvtc=4&fvtv=20697Sanofi and Lilly announce licensing agreement for Cialis(R) (tadalafil) OTC2014-05-28T04:08:17Z<![CDATA[  Sanofi and Lilly announce licensing agreement for Cialis® (tadalafil) OTC]]>https://www.globenewswire.com/news-release/2014/05/05/632767/10079890/en/Shantha-s-Pentavalent-Pediatric-Vaccine-prequalified-by-World-Health-Organization.html?f=22&fvtc=4&fvtv=20697Shantha's Pentavalent Pediatric Vaccine prequalified by World Health Organization2014-05-05T05:06:54Z<![CDATA[- Shan5(TM) is the first vaccine jointly developed by the Indian company
and its parent company Sanofi Pasteur -]]>https://www.globenewswire.com/news-release/2014/01/30/606162/10066347/en/Sanofi-Files-Suit-in-The-U-S-To-Defend-Its-Patent-Rights-on-Lantus-R-and-Lantus-R-SoloStar-R.html?f=22&fvtc=4&fvtv=20697Sanofi Files Suit in The U.S. To Defend Its Patent Rights on Lantus(R) and Lantus(R) SoloStar(R)2014-01-30T22:12:10Z<![CDATA[PARIS, Jan. 30, 2014 (GLOBE NEWSWIRE) -- Sanofi (EURONEXT:SAN) (NYSE:SNY) announced today that it filed a patent infringement suit against Eli Lilly and Company ( "Lilly") on January 30, 2014 in the United States District Court for the District of Delaware. In its suit Sanofi alleges infringement of four patents.]]>